966 Shares in DexCom, Inc. $DXCM Bought by Ameritas Advisory Services LLC

Ameritas Advisory Services LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, HoldingsChannel reports. The firm bought 966 shares of the medical device company’s stock, valued at approximately $84,000.

Several other large investors have also bought and sold shares of the stock. Golden State Wealth Management LLC raised its stake in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after purchasing an additional 264 shares during the period. Zions Bancorporation National Association UT bought a new stake in DexCom in the 1st quarter worth approximately $27,000. Anderson Financial Strategies LLC bought a new stake in DexCom in the 1st quarter worth approximately $37,000. Alpine Bank Wealth Management bought a new stake in DexCom in the 1st quarter worth approximately $40,000. Finally, Private Trust Co. NA lifted its position in DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 335 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 500 shares of the business’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director directly owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,849 shares of company stock valued at $564,733. 0.32% of the stock is owned by insiders.

DexCom Price Performance

Shares of DXCM stock opened at $65.12 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a 50 day moving average price of $74.42 and a 200 day moving average price of $77.62. The firm has a market capitalization of $25.54 billion, a P/E ratio of 45.22, a P/E/G ratio of 1.43 and a beta of 1.47. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom’s revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DXCM. William Blair raised DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Argus initiated coverage on DexCom in a research report on Thursday, August 21st. They set a “buy” rating and a $100.00 price objective on the stock. Barclays increased their target price on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a report on Wednesday, July 30th. Truist Financial began coverage on DexCom in a report on Monday, June 16th. They issued a “buy” rating and a $102.00 target price on the stock. Finally, Raymond James Financial upped their price target on DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $97.42.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.